Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Reduced Activity of GGPPS Mutant is Involved in Bisphosphonates-Induced Atypical Fractures

Michal Lisnyansky, Noa Kapelushnik, Ariel Ben-Bassat, Milit Marom, Anat Loewenstein, Daniel Khananshvili, Moshe Giladi and Yoni Haitin
Molecular Pharmacology October 1, 2018, mol.118.113670; DOI: https://doi.org/10.1124/mol.118.113670
Michal Lisnyansky
1 Tel Aviv University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noa Kapelushnik
1 Tel Aviv University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ariel Ben-Bassat
1 Tel Aviv University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Milit Marom
1 Tel Aviv University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anat Loewenstein
2 Tel Aviv University and Tel Aviv Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Khananshvili
1 Tel Aviv University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Moshe Giladi
1 Tel Aviv University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoni Haitin
1 Tel Aviv University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Bisphosphonates are widely used for treating osteoporosis, a common disorder in which bone strength is reduced, increasing the risk for fractures. Rarely, bisphosphonates can paradoxically lead to atypical fractures occurring spontaneously or with trivial trauma. Recently, a novel missense mutation (D188Y) in the GGPS1 gene, encoding for geranylgeranyl diphosphate synthase (GGPPS), was associated with bisphosphonates- induced atypical fractures. However, the molecular basis for GGPPS involvement in this devastating condition remains elusive. Here, we show that while maintaining an overall unperturbed global enzyme structure, the D188Y mutation leads to a ~4-fold catalytic activity decrease. Furthermore, GGPPS-D188Y is unable to support cross-species complementation, highlighting the functional significance of the reduced catalytic activity observed in vitro. We next determined the crystal structure of apo GGPPS-D188Y, revealing that while Y188 does not alter the protein fold, its bulky side-chain sterically interferes with substrate binding. In agreement, we show that GGPPS-D188Y exhibits ~3-fold reduction in the binding affinity of zoledronate, a commonly used bisphosphonate. However, inhibition of the mutated enzyme by zoledronate, in pharmacologically-relevant concentrations, is maintained. Finally, we determined the crystal structure of zoledronate-bound GGPPS-D188Y, revealing large ligand- induced binding pocket rearrangements, revising the previous model for GGPPS- bisphosphonates interaction. In conclusion, we propose that among heterozygotes residual GGPPS activity is sufficient to support physiological cellular function, concealing any pathologic phenotype. However, under bisphosphonates treatment, GGPPS activity is reduced below a crucial threshold for osteoclasts function, leading to impaired bone remodeling and increased susceptibility to atypical fractures.

  • Bone
  • Enzyme kinetics
  • Osteoclasts
  • Osteoporosis
  • Recombinant proteins
  • Site-directed mutagenesis
  • Structure-activity relationships
  • X-ray crystallography
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Molecular Pharmacology: 99 (2)
Molecular Pharmacology
Vol. 99, Issue 2
1 Feb 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Reduced Activity of GGPPS Mutant is Involved in Bisphosphonates-Induced Atypical Fractures
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Reduced Activity of GGPPS Mutant is Involved in Bisphosphonates-Induced Atypical Fractures

Michal Lisnyansky, Noa Kapelushnik, Ariel Ben-Bassat, Milit Marom, Anat Loewenstein, Daniel Khananshvili, Moshe Giladi and Yoni Haitin
Molecular Pharmacology October 1, 2018, mol.118.113670; DOI: https://doi.org/10.1124/mol.118.113670

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Reduced Activity of GGPPS Mutant is Involved in Bisphosphonates-Induced Atypical Fractures

Michal Lisnyansky, Noa Kapelushnik, Ariel Ben-Bassat, Milit Marom, Anat Loewenstein, Daniel Khananshvili, Moshe Giladi and Yoni Haitin
Molecular Pharmacology October 1, 2018, mol.118.113670; DOI: https://doi.org/10.1124/mol.118.113670
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • P2X7 Positive Modulator Structure-Activity Relationship
  • Predicting Drug Interactions with ENT1 and ENT2
  • GABAAR Molecular Identity in Oligodendrocytes
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics